PD-L1 expression of 742 newly diagnosed advanced respiratory and digestive system tumours in China based on SP142 assay.

被引：0
|
作者：
Chen, Yanhui
Wang, Yating
Yang, Bohang
Hu, Ying
Zeng, Hui
Zhang, Henghui
机构：
[1] Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Lab Emerging Infect Dis, Beijing, Peoples R China
[2] Genecast Precis Med Technol Inst, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Key Lab Emerging Infect Dis, Inst Infect Dis, Beijing Ditan Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24298
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay.
    Scott, Marietta L.
    Scorer, Paul
    Lawson, Nicola
    Ratcliffe, Marianne J.
    Barker, Craig
    Rebelatto, Marlon
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance
    Han, Eun Kyung
    Woo, Ji Won
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Jee Hyun
    Park, So Yeon
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 557 - 566
  • [23] The expression of PD-L1 (Ventana SP142) in HER2-positive breast cancer and its relationship with clinicopathological characteristics
    Zhang, Ningning
    Liu, Yueping
    CANCER RESEARCH, 2021, 81 (04)
  • [24] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio, Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 862 - 862
  • [25] A UK wide survey of PD-L1 expression in triple negative breast cancers (TNBC) as assessed by SP142 assay and correlation with clinicopathological parameters and patient outcomes
    Warren, M.
    Linares, J.
    Khiroya, R.
    Marafioti, T.
    Mackie, S.
    Allen, D.
    HISTOPATHOLOGY, 2022, 81 : 30 - 31
  • [26] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio', Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 862 - 862
  • [27] PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N)
    Ma, Jing
    Li, Jianhui
    Qian, Meirui
    Han, Weili
    Tian, Miaomiao
    Li, Zengshan
    Wang, Zhe
    He, Shuixiang
    Wu, Kaichun
    DIAGNOSTIC PATHOLOGY, 2018, 13
  • [28] SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
    Baek, Seung Ho
    Kim, Jee Hung
    Bae, Soong June
    Ji, Jung Hwan
    Lee, Yangkyu
    Jeong, Joon
    Cha, Yoon Jin
    Ahn, Sung Gwe
    CANCERS, 2022, 14 (13)
  • [29] PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study
    Paliogiannis, Panagiotis
    Lobrano, Renato
    Bella, Michele Angelo
    Fara, Antonella
    Uras, Maria Gabriela
    Pinna, Maria Antonia
    Tedde, Alessandro
    Madonia, Massimo
    Zinellu, Angelo
    Cossu, Antonio
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 69
  • [30] New Approach in the Interpretation of Complex Triple-negative Breast Cancer Immunohistochemistry Specimens Processed With VENTANA PD-L1 (SP142) Assay
    Peg, Vicente
    Abengozar-Muela, Marta
    Acosta, Jesus
    Andres, Leire
    Garcia-Rojo, Marcial
    Hardisson, David
    Nicolau, Maria Jesus
    Ramos-Oliver, Irma
    Rodrigo, Maximiliano
    Sanchez-Bernal, Maria Luisa
    Sanz, Julian
    Garrote, Leia
    Ramirez, Ignacio
    Rojo, Federico
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2025, 33 (01) : 15 - 21
12345